Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy

Prostate

Volumn 71, Issue 16, 2011, Pages 1796-1809

  Reddy, Kavitha Ramasamy ^a   Guan, Yongli ^a   Qin, Guoting ^b   Zhou, Zhou ^a   Jing, Naijie ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Houston   (United States)

Author keywords

HIF 1 ; JG244; Prostate cancer therapy; Stat3; T40214

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; JG 244; STAT3 PROTEIN; T 40214; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054057846     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21397     Document Type: Article

References (41)

1. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R,. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115. (Pubitemid 29077388)
2. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, Tweardy DJ,. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998; 102: 1385-1392. (Pubitemid 28467567)
3. Silvennoinen O, Schindler C, Schlessinger J, Levy DE,. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science 1993; 261: 1736-1739. (Pubitemid 23332923)
4. Darnell JE, Jr., Kerr IM, Stark GR,. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421. (Pubitemid 24217131)
5. Levy DE, Darnell JE, Jr., Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662. (Pubitemid 34987786)
6. Becker S, Groner B, Muller CW,. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998; 394: 145-151. (Pubitemid 28325960)
7. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr., Kuriyan J,. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998; 93: 827-839. (Pubitemid 28257588)
8. Bowman T, Garcia R, Turkson J, Jove R,. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488. (Pubitemid 30339203)
9. Buettner R, Mora LB, Jove R,. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954. (Pubitemid 35177340)
10. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51. (Pubitemid 46020826)
11. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 2009; 9: 798-809.
12. Semenza GL,. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732. (Pubitemid 37328811)
13. Shi YH, Fang WG,. Hypoxia-inducible factor-1 in tumour angiogenesis. World J Gastroenterol 2004; 10: 1082-1087.
14. Powis G, Kirkpatrick L,. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther 2004; 3: 647-654. (Pubitemid 39193744)
15. Hirota K, Semenza GL,. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006; 59: 15-26. (Pubitemid 43903276)
16. Roskoski R, Jr., Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62: 179-213. (Pubitemid 46679285)
17. Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ,. G-quartet oligonucleotides: A new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004; 64: 6603-6609. (Pubitemid 39297920)
18. Jing N, Li Y, Xu X, Sha W, Li P, Feng L, Tweardy DJ,. Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol 2003; 22: 685-696. (Pubitemid 37468167)
19. Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ,. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: A potential novel therapy for head and neck cancer. Mol Cancer Ther 2006; 5: 279-286.
20. Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N,. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol 2007; 31: 129-136.
21. Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N,. T40214/PEI complex: A potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate 2008; 68: 1430-1442.
22. Zhu Q, Jing N,. Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3. J Comput Aided Mol Des 2007; 21: 641-648. (Pubitemid 50005008)
23. Guan Y, Reddy KR, Zhu Q, Li Y, Lee K, Weerasinghe P, Prchal J, Semenza GL, Jing N,. G-rich oligonucleotides inhibit HIF-1alpha and HIF-2alpha and Block Tumor Growth. Mol Ther 2010; 18: 188-197.
24. Jing N, Hogan ME,. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem 1998; 273: 34992-34999. (Pubitemid 29028198)
25. Jing N, Xiong W, Guan Y, Pallansch L, Wang S,. Potassium-dependent folding: A key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors. Biochemistry 2002; 41: 5397-5403. (Pubitemid 34429373)
26. Jing N, Sha W, Li Y, Xiong W, Tweardy DJ,. Rational drug design of G-quartet DNA as anti-cancer agents. Curr Pharm Des 2005; 11: 2841-2854. (Pubitemid 41051870)
27. Pietra LD, Bressan A, Pezzotti AR, Serlupi-Crescenzi O,. Highly conserved amino-acid sequence between murine STAT3 and a revised human STAT3 sequence. Gene 1998; 213: 119-124. (Pubitemid 28284730)
28. Luo G, Gu YZ, Jain S, Chan WK, Carr KM, Hogenesch JB, Bradfield CA,. Molecular characterization of the murine Hif-1 alpha locus. Gene Expr 1997; 6: 287-299.
29. Hambley TW, Hait WN,. Is anticancer drug development heading in the right direction? Cancer Res 2009; 69: 1259-1262.
30. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R,. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-6666. (Pubitemid 35364135)
31. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL,. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586.
32. Lee K, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL,. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 2009; 106: 2353-2358.
33. Goldie H, Walker M, Graham T, Williams F,. Topical effect of acriflavine compounds on growth and spread of malignant cells. J Natl Cancer Inst 1959; 23: 841-855.
34. Grothey A, Galanis E,. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-518.
35. Punt CJ, Tol J,. More is less-Combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol 2009; 6: 731-733.
36. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL,. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613. (Pubitemid 26272112)
37. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K,. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003; 22: 319-329. (Pubitemid 36194328)
38. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE,. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005; 24: 3110-3120. (Pubitemid 40695080)
39. Chun YS, Adusumilli PS, Fong Y,. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia 2005; 10: 311-318. (Pubitemid 44256411)
40. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R,. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86: 558-563. (Pubitemid 34185092)
41. Ishigami SI, Arii S, Furutani M, Niwano M, Harada T, Mizumoto M, Mori A, Onodera H, Imamura M,. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-1384. (Pubitemid 28495254)